Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease

Serena Pelusi, Luca Valenti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the leading cause of advanced liver disease in Western countries. NAFLD is defined in the presence of increased hepatic fat content, which is mainly stored under the form of neutral lipids within intracellular droplets and is not explained by at risk alcohol intake. In order to understand the pathogenesis, monitor the progression and find novel treatments for this condition, previous research efforts mainly addressed the role of inflammation. However, very recent data seem to suggest that hepatic lipid accumulation may be involved in NAFLD pathogenesis by driving secondary inflammation and fibrosis progression. Here, we will briefly review the novel results derived from natural history, genetics, imaging studies and therapeutic trials that support the notion that hepatic fat accumulation may represent a major clinical outcome and therapeutic target for NAFLD. Indeed, prospective and genetic data are consistent with hepatic fat being a driver of NAFLD progression. Furthermore, new technologies will render possible to monitor hepatic fat content without the need of invasive assessment, thereby allowing to identify patients at higher risk, and to monitor the response to drugs that act by decreasing hepatic lipid accumulation.

Original languageEnglish
Pages (from-to)250-256
JournalLiver International
Volume39
Issue number2
DOIs
Publication statusPublished - 2019

Fingerprint

Fats
Liver
Lipids
Therapeutics
Inflammation
Needs Assessment
Natural History
Disease Progression
Non-alcoholic Fatty Liver Disease
Liver Diseases
Fibrosis
Alcohols
Technology
Research
Pharmaceutical Preparations

Keywords

  • clinical outcome
  • non-invasive assessment
  • nonalcoholic fatty liver disease
  • therapy

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. / Pelusi, Serena; Valenti, Luca.

In: Liver International, Vol. 39, No. 2, 2019, p. 250-256.

Research output: Contribution to journalArticle

@article{6c2444b73c544e6b923d1d2c19a78233,
title = "Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the leading cause of advanced liver disease in Western countries. NAFLD is defined in the presence of increased hepatic fat content, which is mainly stored under the form of neutral lipids within intracellular droplets and is not explained by at risk alcohol intake. In order to understand the pathogenesis, monitor the progression and find novel treatments for this condition, previous research efforts mainly addressed the role of inflammation. However, very recent data seem to suggest that hepatic lipid accumulation may be involved in NAFLD pathogenesis by driving secondary inflammation and fibrosis progression. Here, we will briefly review the novel results derived from natural history, genetics, imaging studies and therapeutic trials that support the notion that hepatic fat accumulation may represent a major clinical outcome and therapeutic target for NAFLD. Indeed, prospective and genetic data are consistent with hepatic fat being a driver of NAFLD progression. Furthermore, new technologies will render possible to monitor hepatic fat content without the need of invasive assessment, thereby allowing to identify patients at higher risk, and to monitor the response to drugs that act by decreasing hepatic lipid accumulation.",
keywords = "clinical outcome, non-invasive assessment, nonalcoholic fatty liver disease, therapy",
author = "Serena Pelusi and Luca Valenti",
year = "2019",
doi = "10.1111/liv.13972",
language = "English",
volume = "39",
pages = "250--256",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease

AU - Pelusi, Serena

AU - Valenti, Luca

PY - 2019

Y1 - 2019

N2 - Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the leading cause of advanced liver disease in Western countries. NAFLD is defined in the presence of increased hepatic fat content, which is mainly stored under the form of neutral lipids within intracellular droplets and is not explained by at risk alcohol intake. In order to understand the pathogenesis, monitor the progression and find novel treatments for this condition, previous research efforts mainly addressed the role of inflammation. However, very recent data seem to suggest that hepatic lipid accumulation may be involved in NAFLD pathogenesis by driving secondary inflammation and fibrosis progression. Here, we will briefly review the novel results derived from natural history, genetics, imaging studies and therapeutic trials that support the notion that hepatic fat accumulation may represent a major clinical outcome and therapeutic target for NAFLD. Indeed, prospective and genetic data are consistent with hepatic fat being a driver of NAFLD progression. Furthermore, new technologies will render possible to monitor hepatic fat content without the need of invasive assessment, thereby allowing to identify patients at higher risk, and to monitor the response to drugs that act by decreasing hepatic lipid accumulation.

AB - Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the leading cause of advanced liver disease in Western countries. NAFLD is defined in the presence of increased hepatic fat content, which is mainly stored under the form of neutral lipids within intracellular droplets and is not explained by at risk alcohol intake. In order to understand the pathogenesis, monitor the progression and find novel treatments for this condition, previous research efforts mainly addressed the role of inflammation. However, very recent data seem to suggest that hepatic lipid accumulation may be involved in NAFLD pathogenesis by driving secondary inflammation and fibrosis progression. Here, we will briefly review the novel results derived from natural history, genetics, imaging studies and therapeutic trials that support the notion that hepatic fat accumulation may represent a major clinical outcome and therapeutic target for NAFLD. Indeed, prospective and genetic data are consistent with hepatic fat being a driver of NAFLD progression. Furthermore, new technologies will render possible to monitor hepatic fat content without the need of invasive assessment, thereby allowing to identify patients at higher risk, and to monitor the response to drugs that act by decreasing hepatic lipid accumulation.

KW - clinical outcome

KW - non-invasive assessment

KW - nonalcoholic fatty liver disease

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85055198139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055198139&partnerID=8YFLogxK

U2 - 10.1111/liv.13972

DO - 10.1111/liv.13972

M3 - Article

AN - SCOPUS:85055198139

VL - 39

SP - 250

EP - 256

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 2

ER -